Madrigal Pharmaceuticals Q2 EPS $(4.69) Misses $(4.58) Estimate
Portfolio Pulse from Benzinga Newsdesk
Madrigal Pharmaceuticals reported Q2 losses of $4.69 per share, missing the analyst consensus estimate of $4.58 by 2.4%. This represents a 13.29% increase in losses compared to the same period last year.
August 08, 2023 | 12:24 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Madrigal Pharmaceuticals' Q2 earnings missed analyst estimates, with losses increasing by 13.29% compared to the same period last year.
Madrigal Pharmaceuticals reported higher than expected losses for Q2, missing analyst estimates. This negative earnings surprise could lead to a short-term decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100